accountcompany, announces that new data from the on-going Phase I/II trial of ProSavin(R) for the treatment of Parkinson's disease (PD) were presented at the American Society of Gene & Cell Therapy (ASGCT) 14th Annual Meeting held in Seattle, USA by Professor...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Oxford BioMedica Announces Presentation of New Clinical Data From ProSavin(R) Phase I/II Study in Parkinson's Disease
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account